Epidermal Growth Factor Receptor is Increased in Multidrug-resistant Chinese Hamster and Mouse Tumor Cells
Overview
Affiliations
Multidrug-resistant sublines of Chinese hamster lung and mouse tumor cells selected for high levels of resistance to vincristine or actinomycin D have increased numbers of epidermal growth factor (EGF) receptors compared to control cells. Evidence for this increase was found in six of six resistant cell lines with the use of receptor binding or immunoprecipitation techniques. Levels of 125I-labeled EGF binding to intact actinomycin D-resistant cells derived from DC-3F or CLM-7 Chinese hamster lines are increased 3- to 10-fold compared to controls. Scatchard analysis of these data suggests that increased binding is a result of increased receptor number rather than altered affinity of receptor for ligand. Affinity-labeling and immunoprecipitation studies confirmed the finding of increased receptor amount in resistant hamster and mouse cells. Multidrug-resistant variants of DC-3F cells overproduce a plasma membrane glycoprotein (gp150-180) with several physicochemical properties that resemble those of EGF receptor. However, electrophoretic transfer blots with a polyclonal antibody to gp150-180 show that EGF receptor and gp150-180 are probably different molecules. Resistant cells described in this report manifest a normalized phenotype compared to transformed, tumorigenic, drug-sensitive parental cells. EGF receptor increase in resistant variants may be associated with this reverse transformation.
EGFR-mediated G1/S transition contributes to the multidrug resistance in breast cancer cells.
Chen S, Luan J, Zhang H, Ruan C, Xu X, Li Q Mol Biol Rep. 2011; 39(5):5465-71.
PMID: 22179693 DOI: 10.1007/s11033-011-1347-4.
Fakih M, Wong R Curr Oncol. 2010; 17 Suppl 1:S3-17.
PMID: 20680105 PMC: 2901794. DOI: 10.3747/co.v17is1.616.
Protein kinases and multidrug resistance.
Rumsby M, Drew L, Warr J Cytotechnology. 2008; 27(1-3):203-24.
PMID: 19002793 PMC: 3449563. DOI: 10.1023/A:1008073006495.
Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression.
Huang J, Chen K, Gong W, Zhou Y, Le Y, Bian X Cancer Lett. 2008; 267(2):254-61.
PMID: 18433988 PMC: 4191659. DOI: 10.1016/j.canlet.2008.03.014.
Depenbrock H, Shirvani A, Rastetter J, Hanauske A Invest New Drugs. 1995; 13(3):187-93.
PMID: 8729945 DOI: 10.1007/BF00873799.